Investors are worried about the future of CBD after FDA Commissioner Scott Gottlieb resigned. However, I want to let you know that everything is going to be fine…

I’m not going to sugarcoat it – the stock market was brutal last week.

The Dow Jones Industrial Average fell mostly thanks to a bleak outlook from the European Central Bank and disappointing U.S. job growth numbers for February, and cannabis stocks followed the overall market into a dip.

However, some believe the resignation of FDA Commissioner Scott Gottlieb also pushed cannabis stock prices down. In the stock market, retail investors hate uncertainty. It causes them to expect the worst and panic sell.

For this particular situation, the FDA’s responsibility for regulating CBD is creating some fear that Gottlieb’s eventual replacement will have a harsher stance on regulations.

But I’m here to tell you that, while this is newsworthy, it’s not worth blowing out of proportion.

There is going to be a fight between the FDA and CBD industry – which I will have more about later this week – but it’s not going to be the one you’re hearing about between New York City and coffee shop owners serving CBD-infused cappuccinos.

The picks in our portfolio are going to be just fine, and I even sent out an alert about buying a new cannabis stock because it was a great time to add a position.

So if you’re a cannabis investor, I don’t want you to panic, and I want you to have the full details about what Gottlieb’s resignation really means…

Why We Aren’t Scared of Scott Gottlieb’s Resignation

The most important thing to know is that the 2018 Farm Bill was a game changer for cannabis investors. It legalized the manufacturing, distribution, and sale of hemp-derived products. I’m talking about things like oils, capsules, and tinctures.

In our recent health report, a lot of you talked about using CBD products from Charlotte’s Web Holdings Inc. (CSE: CWEB, OTC: CWBHF).

Manufacturers like that are going to be just fine.

Until recently, Angel Investing was reserved for just 0.1% of investors. However, thanks to a recent law change, average investors now have the chance to break into this lucrative piece of the market. We’re talking about one of the only opportunities for everyday folks to turn $10,000 into $10.5 million. That’s why we’ve gathered one of the industry’s top experts to walk you through this once-in-a-lifetime opportunity. All you have to do is click here to watch the full briefing for yourself.

The FDA wants CBD out of food products simply because it is a regulated drug – it is the active ingredient in Epidiolex, a cannabis-based medicine from GW Pharmaceutical PLC (Nasdaq: GWPH). It’s similar to the FDA not allowing Little Debbie to put aspirin in brownies.

But at much lower dosages, CBD is also a perfectly harmless additive for foods or anything else.

Now, it’s true the next FDA commissioner could conceivably have an anti-CBD agenda, pushing for health officials in cities across the country to follow New York City’s CBD ban. He could have an intense focus on the CBD market, or he might just leave it alone.

I don’t know who will be Gottlieb’s replacement, but I’m not going to lose sleep while we wait for his successor. I will say this: Even the most anti-cannabis people in the Trump administration have not tried to do anything to slow the growth of cannabis. Former Attorney General Jeff Sessions retracted the Cole Memo, but he didn’t initiate any prosecutions outside the guidance of the memo. And there’s no signs that anyone in the administration is hostile towards CBD. President Trump signed the Farm Bill knowing that there was massive hemp reform in it.

If there is ever a reason to sell any of our positions, I will let you know immediately. But this high-level resignation is not one of them.

And even though I know it was a rocky market last week, our investment thesis on why we like our model portfolio members for long-term gains is still strong.

Thanks for being an integral part of the National Institute for Cannabis Investors,


Greg Miller

Executive Director, National Institute for Cannabis Investors

P.S. When was the last time you made $116,800 in 9 months with zero work? That’s exactly what happened to folks who got into Auxly Group on IPO day. All they had to do was put in $2,000 on IPO day and 9 months later they’d be sitting on $109,600 in pure profits. And that’s just the tip of the iceberg. That’s why I sat down with the world’s #1 authority on IPOs. He’s a Wall Street refugee who quit his job at one of the world’s largest investment banks a few years ago to start his own venture capital fund. And in the last 18 months, the IPOs he’s run have made BILLIONS for investors. And all you have to do is click here to listen to what he has to say.


Comments

4 responses to “Scott Gottlieb’s Resignation Won’t Derail the Cannabis Industry”

  1. Norman Sharpless (Ned), current director of the National Cancer Institute (NCI) was just announced to replace Gottlieb’s position. His new title will be Acting Director of the FDA. In the 1980’s Ned coauthored articles that discussed marijuana’s euphorigenic properties in rats. Today, the NCI’s website admits, “cannabis has been used for medicinal purposes for thousands of years.. promoted for reported analgesic, sedative, anti-inflammatory, antispasmodic, and anticonvulsant effects.” Their website even states that physicians were the principal opponents of the Marihuana Tax Act 1937 which made cannabis more difficult to procure. As many cancer patients are users of medicinal marijuana and NCI’s website seems to recognize the benefits of both THC and CBD, Ned Sharpless would likely clear the way for healthcare providers to research and develop cannabis medication.

  2. … [Trackback]

    […] Informations on that Topic: nicinvestors.com/2019/03/11/scott-gottliebs-resignation-wont-derail-the-cannabis-industry/ […]

Leave a Reply

Your email address will not be published. Required fields are marked *